MEGALIN-STRIKER Programs

About Judo Bio

Judo Bio is an early-stage biotech focused on overcoming the historical challenge of delivering genetic medicines to the kidney. Its core innovation is the STRIKE platform, which harnesses endogenous renal recycling receptors, like megalin, for cell-specific delivery of siRNA therapeutics. The company is building a preclinical pipeline targeting solute carrier proteins and other disease-modifying genes, aiming to treat both kidney-specific and systemic conditions. Led by a team with deep experience in oligonucleotide drug development, Judo Bio is positioned to explore a significant unmet medical need in a previously 'undruggable' organ.

Therapeutic Areas